EX-23.1 5 g06286b4exv23w1.htm EX-23.1 CONSENT OF KPMG LLP EX-23.1 CONSENT OF KPMG LLP
EXHIBIT 23.1
 
Consent of Independent Registered Public Accounting Firm
 
The Board of Directors
Cumberland Pharmaceuticals Inc.:
 
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
 
KPMG
 
Nashville, Tennessee
August 12, 2008